loading...| Preferred Name |
Propoxyphene Hydrochloride |
|
| Synonyms |
|
|
| Definitions |
The hydrochloride salt form of the d-isomer of synthetic diphenyl propionate derivative propoxyphene, with narcotic analgesic effect. This agent mimics the effects of the endogenous opiate dextropropoxyphene, by binding to mu receptors located throughout the central nervous system. The binding results in GTP to GDP exchanges on the mu-G-protein complex, by which effector adenylate cyclase is inactivated thereby decreasing intracellular cAMP. This, in turn, inhibits the release of various nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, noradrenaline, vasopressin, and somatostatin. In addition, dextropropoxyphene closes N-type voltage-gated calcium channels and opens calcium-dependent inwardly rectifying potassium channels. This results in hyperpolarization, thereby reducing neuronal excitability, which further decreases the perception of pain. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C29385 |
|
| Accepted_Therapeutic_Use_For |
extravasation resulting from intravenous anthracycline chemotherapy. |
|
| CAS_Registry |
1639-60-7 |
|
| CHEBI_ID |
CHEBI:8498 |
|
| Chemical_Formula |
C22H29NO2.HCl |
|
| code |
C29385 |
|
| Contributing_Source |
FDA |
|
| definition |
The hydrochloride salt form of the d-isomer of synthetic diphenyl propionate derivative propoxyphene, with narcotic analgesic effect. This agent mimics the effects of the endogenous opiate dextropropoxyphene, by binding to mu receptors located throughout the central nervous system. The binding results in GTP to GDP exchanges on the mu-G-protein complex, by which effector adenylate cyclase is inactivated thereby decreasing intracellular cAMP. This, in turn, inhibits the release of various nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, noradrenaline, vasopressin, and somatostatin. In addition, dextropropoxyphene closes N-type voltage-gated calcium channels and opens calcium-dependent inwardly rectifying potassium channels. This results in hyperpolarization, thereby reducing neuronal excitability, which further decreases the perception of pain. |
|
| FDA_UNII_Code |
CB2TL9PS0T |
|
| Has_Free_Acid_Or_Base_Form | ||
| in_subset | ||
| label |
Propoxyphene Hydrochloride |
|
| Legacy Concept Name |
Propoxyphene_Hydrochloride |
|
| NCI_Drug_Dictionary_ID |
508976 |
|
| NCI_META_CUI |
CL449034 |
|
| PDQ_Closed_Trial_Search_ID |
508976 |
|
| PDQ_Open_Trial_Search_ID |
508976 |
|
| Preferred_Name |
Propoxyphene Hydrochloride |
|
| prefixIRI |
NCIT:C29385 |
|
| prefLabel |
Propoxyphene Hydrochloride |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| subClassOf |